Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study

二维码有效期 120s

作者 Chai Meng ^[1] Zhang Haitao ^[2] Yang Lixia ^[1] Liang Jing ^[1] Han Hongya ^[1] Liu Xiaoli ^[1] Ma Xiaoteng ^[1] Liu Yan ^[1] Shi Dongmei ^[1] Zhao Yingxin ^[1] Liu Yuyang ^[1] Zhou Yujie ^[1] 学术成果认领

作者单位 Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing 100029, China ^[1] Department of Cardiology, Air Force Medical Center, Beijing 100142, China ^[2]

栏目名称

Clinical Observation

DOI 10.1097/CM9.0000000000002399

发布时间 2025-04-22

基金项目

National Key Research and Development Program of China（No. 2017YFC0908800）； Beijing Municipal Administration of Hospitals’ Mission plan（No. SML20180601）

浏览9
被引0
下载0

中华医学杂志英文版

2023年136卷11期

1358-1360页

SCIMEDLINEISTICCSCDCABP

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study

Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study

中华医学杂志英文版

相似文献

中华医学杂志英文版

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study

Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study

中华医学杂志英文版

相似文献

中华医学杂志英文版

相关期刊

检索历史清除